Argent Biopharma (RGT) Price & Analysis

Compare

6 Followers

RGT Stock Chart & Stats

AU$0.08

>-AU$0.01(-2.00%)

At close: Jan 08 4:00 PM EST

AU$0.08

>-AU$0.01(-2.00%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.32

Previous CloseN/A

Volume362.25K

Average Volume (3M)77.74K

Market Cap

AU$4.65M

Enterprise ValueAU$11.70M

Total Cash (Recent Filing)AU$1.02M

Total Debt (Recent Filing)AU$8.29M

Price to Earnings (P/E)―

Beta-1.28

Next Earnings

Feb 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding86,942,314

10 Day Avg. Volume131,422

30 Day Avg. Volume77,736

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Gross Margin ImprovementA material uplift in 2025 gross margin suggests the company achieved better product mix or pricing. If sustained, higher gross margins provide more durable operating leverage, improve the pathway to profitability and allow reinvestment in R&D or commercialization as revenue stabilizes.

Improving Free Cash Flow TrendLess-negative free cash flow in 2025 indicates progress reducing cash burn, which can extend the firm's financing runway. A durable trend toward break-even FCF would lower reliance on external capital, reduce dilution risk and strengthen the ability to fund operations or strategic initiatives.

Industry PositioningOperating in specialty and generic pharmaceuticals exposes the company to structural demand for medicines and repeatable revenue streams. Specialty drugs can offer pricing power while generics benefit from steady volume, creating durable market opportunities if the company executes product strategy and compliance.

Bears Say

Sharp Revenue ContractionSevere multi-year revenue declines materially reduce scale, erode bargaining power with suppliers/customers and make fixed costs harder to cover. Sustained top-line shrinkage undermines margin recovery and raises the risk that operational improvements cannot offset lost volume over the medium term.

Negative Equity And Rising LeverageNegative shareholders’ equity and meaningful debt growth indicate elevated solvency risk and constrained financial flexibility. A smaller asset base supporting higher leverage increases default and refinancing risk, which can force costly external financing or asset sales, harming long-term strategic options.

Persistent Cash BurnConsistent and material negative free cash flow shows the business is not self-funding and depends on external capital. Ongoing cash burn pressures liquidity, risks repeated dilutive raises, and limits sustained investment in product development and commercialization necessary to rebuild scale and competitiveness.

Argent Biopharma News

Argent BioPharma Clears Compliance Path for New Share Issue

Argent Biopharma ( ($AU:RGT) ) has shared an announcement. Argent BioPharma has issued 2,557,450 fully paid ordinary shares...

13d ago

Argent Biopharma Seeks ASX Quotation for Over 2.5 Million New Shares

Argent Biopharma ( ($AU:RGT) ) has shared an announcement. Argent Biopharma Limited has applied to the ASX for...

13d ago

Argent BioPharma Clears 1 Million New Shares for On‑Sale Under Corporations Act Exemption

Argent Biopharma ( ($AU:RGT) ) has issued an announcement. Argent BioPharma has issued 1,000,000 fully paid ordinary shares...

1M ago

Argent Biopharma Seeks Quotation of 1 Million New Shares on ASX

Argent Biopharma ( ($AU:RGT) ) has issued an update. Argent Biopharma Limited, listed on the ASX under the...

1M ago

Argent Biopharma Plans Placement of Up to 20 Million New Shares

Argent Biopharma ( ($AU:RGT) ) has provided an announcement. Argent Biopharma Limited has notified the ASX of its...

1M ago

Argent BioPharma Streamlines AusCann Deal to Bolster CannEpil and IP Portfolio

An update from Argent Biopharma ( ($AU:RGT) ) is now available. Argent BioPharma has signed a binding agreement...

1M ago

Argent BioPharma Issues New Shares to Support Clinical Advancements

Argent Biopharma ( ($AU:RGT) ) has issued an announcement. Argent BioPharma has issued 5,616,000 fully paid ordinary shares,...

2M ago

Argent Biopharma Issues Employee Incentive Securities

Argent Biopharma ( ($AU:RGT) ) has shared an update. Argent Biopharma Limited has announced the issuance of 5,000,000...

2M ago

Argent Biopharma Issues New Securities to Creditors

Argent Biopharma ( ($AU:RGT) ) just unveiled an announcement. Argent Biopharma Limited announced the issuance of 616,000 ordinary...

2M ago

Argent BioPharma Restructures Finance Operations Amid Leadership Change

The latest announcement is out from Argent Biopharma ( ($AU:RGT) ). Argent BioPharma has announced the termination of...

3M ago

RGT FAQ

What was Argent Biopharma’s price range in the past 12 months?

Argent Biopharma lowest share price was AU$0.05 and its highest was AU$0.32 in the past 12 months.

What is Argent Biopharma’s market cap?

Argent Biopharma’s market cap is AU$4.65M.

When is Argent Biopharma’s upcoming earnings report date?

Argent Biopharma’s upcoming earnings report date is Feb 27, 2026 which is in 4 days.

How were Argent Biopharma’s earnings last quarter?

Argent Biopharma released its earnings results on Aug 29, 2025. The company reported -AU$0.079 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.079.

Is Argent Biopharma overvalued?

According to Wall Street analysts Argent Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Argent Biopharma pay dividends?

Argent Biopharma does not currently pay dividends.

What is Argent Biopharma’s EPS estimate?

Argent Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Argent Biopharma have?

Argent Biopharma has 86,942,314 shares outstanding.

What happened to Argent Biopharma’s price movement after its last earnings report?

Argent Biopharma reported an EPS of -AU$0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.

Which hedge fund is a major shareholder of Argent Biopharma?

Currently, no hedge funds are holding shares in AU:RGT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Argent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-77.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Argent Biopharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.